ImmuPharma plc (AIM:IMM)

United Kingdom · Delayed Price · Currency is GBP · Price in GBX

3.005

-0.250 (-7.68%)

Nov 5, 2026, 4:40 PM GMT

ImmuPharma Earnings Call Transcripts

Fiscal Year 2026

Investor update
P140 remains the core focus, with licensing deals anticipated this year and strong scientific support. New funding, driven by shareholder interest, enables accelerated development of Kapiglucagon for Type I diabetes, targeting a $3 billion market with a rapid 18–24 month timeline.

Read full transcript →

Press release
Slides